Key Highlights

  • The compliance date for the new mail entry process moves 90 days, to January 20, 2027, from October 22.
  • The original deadline fell 12 days before the November 3 midterm elections, where household affordability is a central issue.
  • A letter signed by 71 members of Congress asked agencies to delay the procedures for prescription medicines.
  • Changes to the de minimis exemption for shipments under USD 800, authorized by Congress, take effect in July 2027.

A 90-Day Reprieve

The US government has delayed by 90 days the implementation of new customs requirements for small international mail shipments. The move postpones the changes until after the November midterm elections, in which affordability concerns for US households are a central issue for President Donald Trump's Republican Party, with control of Congress up for grabs.

US Customs and Border Protection said on Wednesday that it has pushed the mandatory compliance date for a new mail entry process to January 20, 2027, from October 22. The earlier date fell just 12 days before the November 3 elections. The agency said there are no changes to international mail entry procedures before the new date. The new deadline falls 78 days after the vote.

What the Rule Requires

The rule targets the de minimis exemption, which has eased requirements for shipments valued under USD 800. It aims to speed up implementation of changes that lawmakers authorized in Trump's spending and tax-cut bill, which are due to take effect in July 2027.

The process requires electronic filing for postal shipments subject to Section 201, 232 or 301 duties, or under the jurisdiction of a partner government agency such as the Food and Drug Administration. It also involves a customs bond. Trade guidance shows the October 22 date was set 120 days after interim final rules were published on June 24.

Why Drug Imports Are Affected

The Food and Drug Administration officially bars individuals from importing foreign prescription drugs, though it has discretion in limited circumstances. Some Americans order medicines from countries such as Canada, where drug costs can be sharply lower.

As the October 22 deadline approached, patient advocates and industry groups warned of delays, refusals or added costs for personal drug orders stemming from the rule's data and bonding requirements. The Canadian International Pharmacy Association has said most routine personal orders from licensed foreign pharmacies face disruption.

Reaction From Advocates and Lawmakers

A separate letter signed by 71 members of Congress, led by Democratic Representatives Jan Schakowsky of Illinois and Mark Pocan of Wisconsin, asked agencies to delay the procedures for prescription medicines unless personal-use drugs were assured.

The chief executive of a patient advocacy group called the delay a welcome reprieve for patients worried about losing access to lower-cost prescriptions from abroad, but not a permanent solution. She said that until patients in the US can get the drugs they need at prices they can afford, disrupting existing personal-importation practices risks an important safety valve.

Open Questions on Personal Use

The Department of Health and Human Services referred questions to Customs and Border Protection, which did not immediately respond to a request for comment on whether personal-use exemptions are planned. The agency said the extension gives importers, brokers and logistics providers more time to update their processes, helps avoid disruptions and helps close gaps that smugglers have exploited. Its announcement did not mention medicines, and the rule does not name them.